PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar daviecz (36.22) Submitted: 6/10/2011 3:00:20 PM : Outperform Start Price: $5.46 PDLI Score: +15.57

Pharma+++

Report this Post Reply

Featured Broker Partners


Advertisement